MCDC Leadership
Peter Arvan, M.D., Ph.D.
Director, MCDC
Chief, Metabolism, Endocrinology & Diabetes
Brehm Professor of Type 1 Diabetes Research
Dr. Peter Arvan joined the University of Michigan in 2003. He received his undergraduate degree from Cornell University and a doctorate in cell biology from the Yale University School of Medicine where he also pursued his residency and research fellowship in endocrinology. He spent eight years on the faculty at Harvard University working at what is now the Beth Israel-Deaconess Medical Center, and seven years on the faculty of Albert Einstein College of Medicine in New York. In 2003, he joined the University of Michigan as chief of the Division of Metabolism, Endocrinology & Diabetes to assume the Brehm Professorship and brought along a large portion of his research team.
Dr. Arvan’s research focuses on increasing medicine’s understanding of insulin synthesis and secretion, and how insulin synthesis is linked to pancreatic beta cell survival (or demise) in normal individuals and people with diabetes.
Dr. Arvan is a past recipient of a PEW Foundation scholarship in the biomedical
sciences, a Wellcome Visiting Professorship in the basic medical sciences and
winner of the R.R. Bensley award from the American Association of Anatomy.
He is Principal Investigator on two NIH-funded RO1 grants and consults on a third. He also has been awarded funding from the American Diabetes Association.
He has served as a reviewer for 15 specialty journals and is currently
on the editorial board of the American Journal of Physiology: Endocrinology
and Metabolism. He also is a member of numerous scientific societies and
is frequently invited to speak at national and international conferences.
Since 2003, Arvan has established his clinical practice and has been recently
named one of Hour Detroit Magazine’s “2006 Top Docs.”
Frank C. Brosius III, M.D.
Director, Animal Models of Diabetes Complications Consortium
Division Chief, Nephrology
Professor, Internal Medicine
Professor, Molecular & Integrative
Physiology
Dr. Frank C. Brosius has been the director of the University of Michigan/University of Chicago unit in the Animal Models of Diabetes Complications Consortium for the past five years. In the renewal of the AMDCC, Dr. Brosius is a Principal Investigator of one of the Pathobiology sites for the Consortium and has been selected as Chair-elect of the Steering Committee of the AMDCC.
Dr. Brosius received his medical degree from the University of Kansas and completed his residency at the University of Michigan. Prior to joining the U-M faculty, Dr. Brosius completed fellowships at the National Institutes of Health in Bethesda, Maryland, the Beth Israel Hospital in Boston, Massachusetts, and his post doctorate at the Whitehead Institute in Cambridge, Massachusetts.
Dr. Brosius’ research interest focuses on curing and stabilizing diabetic kidney disease, and understanding how glucose transport leads to altered kidney and vascular function in diabetic kidney disease and hypertension.
Charles F. Burant, M.D., Ph.D.
Director, Michigan Metabolomics and Obesity Center
Professor, Internal Medicine
Professor, Molecular & Integrative Physiology
Adjunct Associate Professor, Kinesiology
Robert C. and Veronica Atkins Professor of Metabolism
As director of the Michigan Metabolomics and Obesity Center, Dr. Charles F. Burant facilitates the network of obesity related researchers on the U-M campus which results in enhancing collaborative studies and speeding the translation of basic science findings into clinically useful therapies for metabolic diseases including obesity, Type 2 diabetes and related metabolic disorders.
Dr. Burant earned both his medical degree and doctorate of philosophy
in molecular and cellular biology from the Medical University of
South Carolina in Charleston. His internship and residency were served
at the University of California, San Francisco, and he completed his
fellowship in the Department of Medicine, Endocrinology Section at the
University of Chicago. He joined the University of Michigan
faculty in 1999.
Eva L. Feldman, M.D., Ph.D.
Director, Juvenile Diabetes Research Foundation for the Study
of Complications in Diabetes
Director. Amyotrophic Lateral Sclerosis
Clinic
Russell N. DeJong Professor
of Neurology
Dr. Eva Feldman is the director of the Juvenile Diabetes Research Foundation for the Study of Complications in Diabetes, the Russell N. DeJong Professor of Neurology, and is the director for the Amyotrophic Lateral Sclerosis (ALS) Clinic.
Dr. Feldman received her medical degree from the University of Michigan and completed a neurology residency at the Johns Hopkins Hospital where she served as Chief Resident. She completed a fellowship in clinical neuromuscular disease at the University of Michigan and officially joined the University of Michigan Medical Center in 1988.
Dr. Feldman's current investigative activities emphasize an understanding of the pathogenesis and treatment of neuromuscular disorders with an emphasis on diabetic neuropathy and ALS.
William H. Herman, M.D., M.P.H.
Director, Michigan Diabetes Research and Training Center
Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes
Dr. William H. Herman serves as Director for the Michigan Diabetes Research and Training Center and Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes.
Dr. Herman received his medical degree from Boston University, a master of public health in epidemiology at University of Michigan, and joined the University of Michigan faculty in 1995.
Dr. Herman’s research focuses on diabetes, its treatments and complications. In addition he studies diabetes epidemiology, managed care and health economics.
